Analgesia and Sedation in Critically Ill Adult Patients Admitted to a COVID-19 Intensive Care Unit

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the COVID-19 has spread globally, prompting world health organization (WHO) to declare COVID-19 a pandemic. As of January 2, 2021, about 82,579,768 laboratory-confirmed COVID-19 cases had been reported to the WHO with 1,818,849 deaths (https://covid19.who.int). The pandemic has severely impacted health care systems around the world, resulting in a vast number of surgical procedures being cancelled or postponed and an unprecedented burden on intensive care units (ICU). A critical component of the perioperative or ICU services delivery is the provision of analgesia and sedation. Volatile inhalational anesthetics combined with opioids are widely used in an operating room, whereas in ICUs, intravenous drugs are used for this purpose. Although target-controlled infusions are not routinely used in ICUs, in the context of the thematic series on total intravenous anesthesia during COVID-19 pandemic, this article will focus on key aspects of intravenous sedation and analgesia in the management of critically ill patients admitted to an ICU following positive swab test for SARS-CoV-2 RNA